Ind-Swift Laboratories delivered remarkable financial performance in the quarter ended June 2026, with consolidated net profit surging 183.5% YoY and 28.9% QoQ to ₹24.86 crore compared to ₹8.77 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this exceptional profit growth demonstrates the company's strong operational efficiency and market positioning during the quarter.
The company's sales revenue increased 25.3% YoY and 12.8% QoQ to ₹191.45 crore in Q1 FY2026, up from ₹152.73 crore in the same quarter of the previous financial year. As reported by Business Standard, this revenue growth indicates robust demand for the company's pharmaceutical products and successful market expansion strategies during the quarter.
Operating profit margin (OPM) improved to 17.47% in the June 2026 quarter compared to 2.36% in the corresponding quarter of the previous year. According to the financial data reported by Business Standard, this significant improvement in operational efficiency contributed to the substantial profit growth despite the company's expansion in sales revenue.
Profit before tax (PBT) increased 214.3% YoY and 172.2% QoQ to ₹32.56 crore in the quarter ended June 2026, compared to ₹10.35 crore in the same quarter of the previous year. As reported by Business Standard, this substantial increase in pre-tax profit indicates strong operational performance and effective cost management during the quarter.
On the cost front, total expenses increased 6.3% YoY and 5.3% QoQ to ₹165.60 crore. Raw material consumption rose 25.0% YoY to ₹81.76 crore, while employee expenses increased 21.6% YoY to ₹39.56 crore. Interest costs declined 38.3% YoY to ₹0.71 crore, and depreciation and amortisation expenses increased 13.5% YoY to ₹7.58 crore. Other income declined 47.5% YoY to ₹7.65 crore but jumped 244.6% QoQ.
The board approved the sale of around 40 bighas (approximately 10 acres) of land at Village Behra, Derabassi, Punjab, for ₹17.50 crore. The land, which was earlier purchased for setting up a manufacturing facility, is being sold after being found unsuitable for a finished dosages facility under applicable international regulatory and registration requirements. The transaction is proposed to be completed within nine months, subject to the terms and conditions of the agreement.
Ind-Swift Laboratories shares gained 18.19% to ₹280.40 following the strong quarterly results announcement. The stock has shown positive momentum with a weekly return of 3.77%, reflecting investor confidence in the company's robust financial performance and growth prospects in the pharmaceutical sector. The company is engaged in manufacturing a wide range of formulations including tablets, capsules, ointments, injectables, liquids and dry syrups.
